| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d3ba6f026ef5776ed3a79d2944f81a87 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-55572 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12P19-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H11-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-739
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H13-06 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12R1-01 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-54
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H13-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-739
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-09
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C08B37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P19-26
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-39
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H13-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H11-04 |
| filingDate |
1998-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6f776beb2db5dee2b009a2db3cb87743
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c82d2af6e9bc0073ca3bea5e8a0dfa6b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_88e9d5e9bbf99677e439ba0e7ca26135 |
| publicationDate |
2001-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
EP-1127137-A1 |
| titleOfInvention |
Lps with reduced toxicity from genetically modified gram negative bacteria |
| abstract |
The subject invention lies in the field of vaccines. Specifically new compounds that can be used as adjuvants are provided. Recombinant LPS having a reduced number of secondary acyl chains per molecule of LPS vis a vis the corresponding non modified LPS molecule, said secondary acyl chains being bound to primary acyl chains, said primary acyl chains being bound to the glucosamine of said recombinant LPS molecule, said recombinant LPS being homogenous in acylation pattern is an example of such a compound. Also recombinant LPS having a phosphate group attached to the glucosamine at the non-reducing end of the LPS molecule and a phosphate group attached to the glucosamine at the reducing end of the molecule per recombinant LPS molecule provides a further example. |
| priorityDate |
1998-11-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |